These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 30323548)

  • 41. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group.
    Stevenson D; Tauber J; Reis BL
    Ophthalmology; 2000 May; 107(5):967-74. PubMed ID: 10811092
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Results from a Prospective, Open-Label, Phase 4 Pilot Study of Repository Corticotropin Injection for Moderate and Severe Dry Eye Disease.
    Toyos M; Toyos R; Jodoin B; Bunch R
    Ophthalmol Ther; 2022 Jun; 11(3):1231-1240. PubMed ID: 35460497
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Quantum molecular resonance electrotherapy (Rexon-Eye) for recalcitrant dry eye in an Asian population.
    Foo VHX; Liu YC; Tho B; Tong L
    Front Med (Lausanne); 2023; 10():1209886. PubMed ID: 37771976
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Short-term tolerability of once-daily timolol hemihydrate 0.5%, timolol maleate in sorbate 0.5%, and generic timolol maleate gel-forming solution 0.5% in glaucoma and/or ocular hypertension: a prospective, randomized, double-masked, active-controlled, three-period crossover pilot study.
    Sonty S; Mundorf TK; Stewart JA; Stewart WC
    Clin Ther; 2009 Oct; 31(10):2063-71. PubMed ID: 19922877
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial.
    Amparo F; Dastjerdi MH; Okanobo A; Ferrari G; Smaga L; Hamrah P; Jurkunas U; Schaumberg DA; Dana R
    JAMA Ophthalmol; 2013 Jun; 131(6):715-723. PubMed ID: 23599118
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A phase 2a, double-masked, randomized, vehicle-controlled trial of VVN001 in subjects with dry eye disease.
    Tauber J; Evans D; Segal B; Li XY; Shen W; Lu C; Novack GD;
    Ocul Surf; 2023 Apr; 28():18-24. PubMed ID: 36586669
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Early Onset and Broad Activity of Reproxalap in a Randomized, Double-Masked, Vehicle-Controlled Phase 2b Trial in Dry Eye Disease.
    Clark D; Tauber J; Sheppard J; Brady TC
    Am J Ophthalmol; 2021 Jun; 226():22-31. PubMed ID: 33529588
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye.
    Meerovitch K; Torkildsen G; Lonsdale J; Goldfarb H; Lama T; Cumberlidge G; Ousler GW
    Clin Ophthalmol; 2013; 7():1275-85. PubMed ID: 23836957
    [TBL] [Abstract][Full Text] [Related]  

  • 49. n-3 Fatty Acid Supplementation for the Treatment of Dry Eye Disease.
    ; Asbell PA; Maguire MG; Pistilli M; Ying GS; Szczotka-Flynn LB; Hardten DR; Lin MC; Shtein RM
    N Engl J Med; 2018 May; 378(18):1681-1690. PubMed ID: 29652551
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye.
    Semba CP; Torkildsen GL; Lonsdale JD; McLaurin EB; Geffin JA; Mundorf TK; Kennedy KS; Ousler GW
    Am J Ophthalmol; 2012 Jun; 153(6):1050-60.e1. PubMed ID: 22330307
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model.
    Sosne G; Ousler GW
    Clin Ophthalmol; 2015; 9():877-84. PubMed ID: 26056426
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dexamethasone Intracanalicular Insert for Clinically Significant Aqueous-Deficient Dry Eye: A Randomized Controlled Trial.
    Lin MX; Guo L; Saldanha IJ; VanCourt S; Zeng J; Karakus S; Hessen M; Li G; Akpek EK
    Ophthalmology; 2024 Mar; ():. PubMed ID: 38492864
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of novel lipid-based eye drops with aqueous eye drops for dry eye: a multicenter, randomized controlled trial.
    Simmons PA; Carlisle-Wilcox C; Vehige JG
    Clin Ophthalmol; 2015; 9():657-64. PubMed ID: 25931806
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye.
    Tauber J; Davitt WF; Bokosky JE; Nichols KK; Yerxa BR; Schaberg AE; LaVange LM; Mills-Wilson MC; Kellerman DJ
    Cornea; 2004 Nov; 23(8):784-92. PubMed ID: 15502479
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and Safety of Sodium Hyaluronate/chondroitin Sulfate Preservative-free Ophthalmic Solution in the Treatment of Dry Eye: A Clinical Trial.
    Belalcázar-Rey S; Sánchez Huerta V; Ochoa-Tabares JC; Altamirano Vallejo S; Soto-Gómez A; Suárez-Velasco R; García-Félix F; Baiza-Durán L; Olvera-Montaño O; Muñoz-Villegas P
    Curr Eye Res; 2021 Jul; 46(7):919-929. PubMed ID: 33289602
    [No Abstract]   [Full Text] [Related]  

  • 56. Autologous serum eye drops for dry eye.
    Pan Q; Angelina A; Marrone M; Stark WJ; Akpek EK
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD009327. PubMed ID: 28245347
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of 0.05% cyclosporine and 3% diquafosol solution for dry eye patients: a randomized, blinded, multicenter clinical trial.
    Park CH; Lee HK; Kim MK; Kim EC; Kim JY; Kim TI; Kim HK; Song JS; Yoon KC; Lee DH; Chung TY; Choi CY; Kim HS
    BMC Ophthalmol; 2019 Jun; 19(1):131. PubMed ID: 31208393
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial.
    Sosne G; Dunn SP; Kim C
    Cornea; 2015 May; 34(5):491-6. PubMed ID: 25826322
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Repository Corticotropin Injection (Acthar
    Wirta D; McLaurin E; Ousler G; Liu J; Kacmaz RO; Grieco J
    Ophthalmol Ther; 2021 Dec; 10(4):1077-1092. PubMed ID: 34669183
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-Term Safety and Efficacy of a Water-Free Cyclosporine 0.1% Ophthalmic Solution for Treatment of Dry Eye Disease: ESSENCE-2 OLE.
    Wirta DL; Galor A; Aune CA; Vollmer PM; Liang E; Meides AS; Krösser S
    Cornea; 2024 May; ():. PubMed ID: 38771801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.